GlassScriptPhysician profile
Alicia Loper
NPI 1144795782
$1,908.08
in general payments reported to CMS, 2019-2025
22 companies · $935 in 2025
The $935 reported for 2025 was more than what 84% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
See the full distribution for Gerontology (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $63.00 · 2023: $354 · 2024: $556 · 2025: $935.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,845.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,845.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $683.81 | 2023-2025 | |
| Pfizer INC. | $162.92 | 2025 | |
| Astellas Pharma US INC | $142.18 | 2025 | Veozah |
| Novo Nordisk INC | $127.31 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Exact Sciences Corporation | $103.41 | 2023-2024 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $86.79 | 2024-2025 | Airsupra |
| Takeda Pharmaceuticals U.S.A., INC. | $79.96 | 2023-2025 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $70.92 | 2024-2025 | Xifaxan |
| Mayne Pharma Commercial LLC | $67.02 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $63.00 | 2022 | |
| Exeltis, USA INC. | $42.47 | 2023-2024 | Slynd |
| Idorsia Pharmaceuticals US INC | $41.99 | 2023 | Quviviq |
| Shield Therapeutics INC | $37.56 | 2023 | Accrufer |
| Hologic Sales and Service, LLC | $34.98 | 2025 | Aptima |
| Boston Scientific Corporation | $27.69 | 2024 | Bodyguardian |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $26.54 | 2024 | Strensiq |
| Ars Pharmaceuticals Operations, INC. | $22.96 | 2025 | Neffy |
| Bayer Healthcare Pharmaceuticals INC. | $19.67 | 2024 | |
| Phadia US INC. | $18.31 | 2024 | Immunocap |
| Tris Pharma INC | $17.77 | 2023 | Dyanavel Xr |
| Currax Pharmaceuticals LLC | $16.52 | 2025 | Contrave |
| Becton, Dickinson and Company | $14.30 | 2024 | Bd Onclarity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alicia Loper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.